Table 4. Significant Spearman rank-correlations with R-values > 0.20 between intratumoral and stromal CD66b+ TANs and tumor-associated markers in samples from NSCLC in the total cohort and in subgroups according to histology (Total cohort = 326, SCC = 191; ADC = 95).
ALL | SCC | ADC | ||||||
---|---|---|---|---|---|---|---|---|
Correlations with markers expressed in intratumoral cells | ||||||||
Tumor | Stroma | Tumor | Stroma | Tumor | Stroma | |||
CAIX | 0.23* | ANG | T | |||||
CD34 | −0.27** | −0.27** | ANG | T | ||||
D240 | 0.21* | ANG | T | |||||
DLL4 | −0.20*** | −0.24* | ANG | T | ||||
FGFR1 | −0.23* | ANG | T | |||||
Glut1 | 0.28** | ANG | T | |||||
NOTCH1 | 0.25* | ANG | T | |||||
NOTCH4 | −0.22** | ANG | T | |||||
PHD-3 | −0.33*** | ANG | T | |||||
Bad-cyt | −0.24*** | −0.21* | −0.22* | EMT | T | |||
Bad-Nuc | −0.24** | EMT | T | |||||
Her3 | −0.21** | EMT | T | |||||
Ki67 | 0.22* | EMT | T | |||||
pHer2 | −0.22** | EMT | T | |||||
pi3K | −0.21*** | EMT | T | |||||
CD66b | 0.76# | 0.80# | 0.66# | IMM | T | |||
CD68 | 0.23# | 0.28*** | 0.28# | IMM | T | |||
MCT1 | 0.22* | MET | T | |||||
MCT4 | 0.22# | 0.22** | 0.27# | MET | T | |||
PGC1-α | −0.23* | MET | T | |||||
Correlations with markers expressed in tumor stroma | ||||||||
Tumor | Stroma | Tumor | Stroma | Tumor | Stroma | |||
Ang2 | 0.21* | ANG | S | |||||
D240 | 0.24* | ANG | S | |||||
DLL4 | 0.21** | ANG | S | |||||
miR21 | 0.21*** | 0.23* | ANG | S | ||||
NOTCH4 | 0.21** | ANG | S | |||||
PDGF-A | 0.22** | 0.23** | 0.23* | ANG | S | |||
VEGF-A | 0.22** | ANG | S | |||||
VEGF-D | 0.21** | 0.21* | ANG | S | ||||
cAkt | 0.24*** | EMT | S | |||||
ERK3 | 0.20** | EMT | S | |||||
IGF1 | 0.21** | EMT | S | |||||
NfκB | 0.23** | EMT | S | |||||
PAR6 | 0.22** | EMT | S | |||||
CD138 | 0.21** | IMM | S | |||||
CD1a | 0.20** | IMM | S | |||||
CD66b | 0.76# | 0.80# | 0.66# | IMM | S | |||
CSF1R | 0.23# | 0.25# | 0.26*** | 0.28# | 0.23* | 0.21* | IMM | S |
CXCL16 | 0.25*** | IMM | S | |||||
FOXP3 | 0.21** | IMM | S | |||||
CD68 | 0.23# | 0.23** | 0.27# | IMM | S | |||
MCSF | 0.28# | 0.25# | 0.32# | 0.32# | IMM | S | ||
FOXO1A | 0.28# | IMM | S | |||||
LDH5 | 0.24*** | MET | S | |||||
MCT1 | 0.23# | 0.26# | 0.23** | 0.30# | 0.28** | 0.24* | MET | S |
MCT4 | 0.22# | 0.20*** | 0.20** | 0.23* | 0.27** | MET | S |
Abbreviations: CD, cluster of differentiation; SCC, squamous cell carcinoma; ADC, adenocarcinoma;ANG, angiogenesis; EMT, epithelial-mesenchymal transition; MET, metastasis; IMM; immunology; CAIX, Anti-Carbonic Anhydrase IX;DLL4, Delta ligand 4; FGFR1, Fibroblast Growth Factor Receptor 1; GLUT1, Glucose transporter 1; PHD, prolyl hydroxylase-domain; BAD, Bcl2 Associated Death Promoter; Cyt, in cytoplasm; Nuc, in nucleus; Her, human epidermal growth factor receptor; MCT, monocarboxylate transporter; PGC1, Peroxisome proliferative activated receptor gamma coactivator 1; Ang, angiogenin; miR, micro RNA; PDGF, Platelet-derived growth factor; VEGF, Vascular endothelial growth factor; IGF1, Insulin like growth factor 1; PAR6, Partitioning defective 6; CXCL16, C-X-C motif ligand; FOX, forkhead box; MCSF, Macrophage Colony Stimulating Factor 1; CSF1R, Colony stimulating factor 1 receptor; LDH, lactate dehydrogenase.
significant at p > 0.05,
significant at p > 0.01,
significant at p >0.001,
significant after Bonferroni correction for multiple tests